Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
Holding AU:NEU?
Track your performance easily
NEU Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$12.02 - AU$25.95
Previous CloseAU$16.71
Volume123.59K
Average Volume (3M)531.25K
Market Cap
AU$2.17B
Enterprise ValueAU$2.13B
Total Cash (Recent Filing)AU$40.18M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)18.1
Beta0.78
Next Earnings
Mar 04, 2025EPS Estimate
AU$0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares OutstandingN/A
10 Day Avg. Volume738,168
30 Day Avg. Volume531,249
Standard Deviation0.25
R-Squared0.22
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)123.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$28.85Price Target Upside72.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Neuren Pharmaceuticals Limited News
PremiumCompany Announcements
Neuren Pharmaceuticals’ Commitment to Neurodevelopmental Care
PremiumCompany Announcements
Neuren Pharmaceuticals Unveils A$50 Million Share Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Strong Q3 Financial Growth
PremiumCompany Announcements
Neuren Pharmaceuticals Gains from Voucher Sale
PremiumCompany Announcements
Neuren Pharmaceuticals Updates Policy Amid Financial GrowthPremiumCompany Announcements
Neuren’s DAYBUE Gains Canadian Approval, Expanding Market
PremiumCompany Announcements
Neuren Pharmaceuticals Advances PMS Treatment TrialsPremiumCompany Announcements
Neuren Pharmaceuticals Sees Surge in H1 RevenueOptions Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
2.81% Mutual Funds
<0.01% Other Institutional Investors
94.16% Public Companies and
Individual Investors
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$12.02 and its highest was AU$25.95 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Mar 04, 2025 which is in 107 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Aug 27, 2024. The company reported AU$0.061 earnings per share for the quarter, missing the consensus estimate of AU$0.11 by -AU$0.049.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is AU$0.89.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 130,065,670 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.061 in its last earnings report, missing expectations of AU$0.11. Following the earnings report the stock price went down -2.603%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
---
Neuren Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$28.85 (72.03% Upside)
AU$28.85 (72.03% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 97%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.65%
12-Months-Change
Fundamentals
Return on Equity
73.89%
Trailing 12-Months
Asset Growth
134.72%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
---
NEU Company Deck
---
NEU Earnings Call
Q4 2024
0:00 / 0:00
---
NEU Stock 12 Month Forecast
Average Price Target
AU$28.85
▲(72.03% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
ANI Pharmaceuticals
―
Axsome Therapeutics
―
Bioxcel Therapeutics
―
Neuren Pharmaceuticals Limited
―
Best Analysts Covering NEU
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+25.17%
reiterated a buy rating 10 days ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +25.17% per trade.
---